☰

Markos Leggas, Ph.D. - Publications

Affiliations: 
2004 University of Tennessee Health Science Center, Memphis, TN, United States 
Area:
Biomedical Engineering, Pharmacology
Tree Info Grants Similar researchers Related pubs Distance to... Nearest Nobel PubMed Report error

36 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Eckenrode JM, Mitra P, Rohr J, Leggas M. Bioanalytical method for quantitative determination of mithramycin analogues in mouse plasma by HPLC-QTOF. Biomedical Chromatography : Bmc. e4544. PMID 30927450 DOI: 10.1002/Bmc.4544  0.325
2019 Tang F, Tsakalozou E, Arnold SM, Ng CM, Leggas M. Population pharmacokinetic analysis of AR-67, a lactone stable camptothecin analogue, in cancer patients with solid tumors. Investigational New Drugs. PMID 30820810 DOI: 10.1007/S10637-019-00744-0  0.34
2019 Hayden RC, Hou C, Mitra P, Mandal A, Rohr J, Thorson J, Tsodikov O, Leggas M. Abstract 2954: Mithramycin analogues disrupt ETS transcription factor DNA binding Cancer Research. 79: 2954-2954. DOI: 10.1158/1538-7445.Sabcs18-2954  0.319
2018 Ye Q, Zhang Y, Cao Y, Wang X, Guo Y, Chen J, Horn J, Ponomareva LV, Chaiswing L, Shaaban KA, Wei Q, Anderson BD, St Clair DK, Zhu H, Leggas M, et al. Frenolicin B Targets Peroxiredoxin 1 and Glutaredoxin 3 to Trigger ROS/4E-BP1-Mediated Antitumor Effects. Cell Chemical Biology. PMID 30661989 DOI: 10.1016/J.Chembiol.2018.11.013  0.315
2018 Leggas M, Eckenrode J, Mitra P, Jha A, Salem S, Mandal A, Thorson J, Rohr J. Abstract B043: Mithramycin-SA analogues with reduced toxicity for the treatment of ETS transcription factor-driven tumors Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B043  0.325
2015 Wang Y, Liu X, Pijut SS, Li J, Horn J, Bradford EM, Leggas M, Barrett TA, Graf GA. The combination of ezetimibe and ursodiol promotes fecal sterol excretion and reveals a G5G8-independent pathway for cholesterol elimination. Journal of Lipid Research. 56: 810-20. PMID 25635125 DOI: 10.1194/Jlr.M053454  0.304
2015 Eckenrode J, Horn J, Chen J, Rohr J, Leggas M. Abstract 2628: Mithramycin analogs with reduced toxicity for EWS-FLI1 targeting Cancer Research. 75: 2628-2628. DOI: 10.1158/1538-7445.Am2015-2628  0.363
2013 Penthala NR, Sonar VN, Horn J, Leggas M, Yadlapalli JS, Crooks PA. Synthesis and evaluation of a series of benzothiophene acrylonitrile analogs as anticancer agents. Medchemcomm. 4: 1073-1078. PMID 23956835 DOI: 10.1039/C3Md00130J  0.364
2013 Hollis CP, Weiss HL, Leggas M, Evers BM, Gemeinhart RA, Li T. Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery. Journal of Controlled Release : Official Journal of the Controlled Release Society. 172: 12-21. PMID 23920039 DOI: 10.1016/J.Jconrel.2013.06.039  0.339
2013 Tsakalozou E, Adane ED, Kuo KL, Daily A, Moscow JA, Leggas M. The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1404-13. PMID 23620484 DOI: 10.1124/Dmd.112.050021  0.396
2012 Ahmed TA, Horn J, Hayslip J, Leggas M. Validated LC-MS/MS method for simultaneous determination of SIM and its acid form in human plasma and cell lysate: Pharmacokinetic application. Journal of Pharmaceutical Analysis. 2: 403-411. PMID 29403775 DOI: 10.1016/J.Jpha.2012.07.010  0.315
2012 Kim JK, Yuan H, Nie J, Yang YT, Leggas M, Potter PM, Rinehart J, Jay M, Lu X. High payload dual therapeutic-imaging nanocarriers for triggered tumor delivery. Small (Weinheim An Der Bergstrasse, Germany). 8: 2895-903. PMID 22777758 DOI: 10.1002/Smll.201200437  0.301
2012 Kuo KL, Zhu H, McNamara PJ, Leggas M. Localization and functional characterization of the rat Oatp4c1 transporter in an in vitro cell system and rat tissues. Plos One. 7: e39641. PMID 22768102 DOI: 10.1371/Journal.Pone.0039641  0.327
2012 Adane ED, Liu Z, Xiang TX, Anderson BD, Leggas M. Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats. Pharmaceutical Research. 29: 1722-36. PMID 22068278 DOI: 10.1007/S11095-011-0617-0  0.318
2012 Ahmed T, Hayslip J, Leggas M. Abstract 3778: Pharmacokinetic, safety and efficacy of high dose simvastatin in refractory and relapsed chronic lymphocytic leukemia (CLL) patients Cancer Research. 72: 3778-3778. DOI: 10.1158/1538-7445.Am2012-3778  0.364
2011 Tsakalozou E, Howard D, Leggas M. Abstract 3547: In vitro and ex vivo anti-leukemia activity of AR-67, a novel lipophilic camptothecin Cancer Research. 71: 3547-3547. DOI: 10.1158/1538-7445.Am2011-3547  0.359
2011 Leggas M, Tsakalozou E, Ahmed T, Kuo K, Horn J, Penthala N, Crooks P. Abstract C216: Small molecule antitubulin drugs that evade multiple drug resistance mechanisms. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C216  0.389
2011 Ahmed T, Hayslip J, Leggas M. Abstract A78: Simvastatin synergistically potentiates tipifarnib cytotoxic and apoptotic effects and disrupts Ras membrane localization in human leukemia cells. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A78  0.323
2010 Adane ED, Liu Z, Xiang TX, Anderson BD, Leggas M. Factors affecting the in vivo lactone stability and systemic clearance of the lipophilic camptothecin analogue AR-67. Pharmaceutical Research. 27: 1416-25. PMID 20428932 DOI: 10.1007/S11095-010-0137-3  0.327
2010 Daily A, Monks NR, Leggas M, Moscow JA. Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibition. Toxicon : Official Journal of the International Society On Toxinology. 55: 827-37. PMID 19944114 DOI: 10.1016/J.Toxicon.2009.11.019  0.359
2009 Ma P, Dong X, Swadley CL, Gupte A, Leggas M, Ledebur HC, Mumper RJ. Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia. Journal of Biomedical Nanotechnology. 5: 151-61. PMID 20055093 DOI: 10.1166/Jbn.2009.1021  0.356
2009 Wilson MW, Fraga CH, Rodriguez-Galindo C, Hagedorn N, Leggas ML, Stewart C. Expression of the multi-drug resistance proteins and the pregnane X receptor in treated and untreated retinoblastoma. Current Eye Research. 34: 386-94. PMID 19401882 DOI: 10.1080/02713680902859621  0.461
2009 Lu X, Howard MD, Talbert DR, Rinehart JJ, Potter PM, Jay M, Leggas M. Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release. The Aaps Journal. 11: 120-2. PMID 19225893 DOI: 10.1208/S12248-009-9086-3  0.302
2008 Wang L, Leggas M, Goswami M, Empey PE, McNamara PJ. N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) as a chemical ATP-binding cassette transporter family G member 2 (Abcg2) knockout model to study nitrofurantoin transfer into milk. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 2591-6. PMID 18799806 DOI: 10.1124/Dmd.108.021980  0.303
2008 Vore M, Leggas M. Progesterone acts via progesterone receptors A and B to regulate breast cancer resistance protein expression. Molecular Pharmacology. 73: 613-5. PMID 18086804 DOI: 10.1124/Mol.107.044289  0.382
2007 Takenaka K, Morgan JA, Scheffer GL, Adachi M, Stewart CF, Sun D, Leggas M, Ejendal KF, Hrycyna CA, Schuetz JD. Substrate overlap between Mrp4 and Abcg2/Bcrp affects purine analogue drug cytotoxicity and tissue distribution. Cancer Research. 67: 6965-72. PMID 17638908 DOI: 10.1158/0008-5472.Can-06-4720  0.565
2006 Horn J, Jordan SL, Song L, Roberts MJ, Anderson BD, Leggas M. Validation of an HPLC method for analysis of DB-67 and its water soluble prodrug in mouse plasma. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 844: 15-22. PMID 16860004 DOI: 10.1016/J.Jchromb.2006.06.022  0.302
2006 Leggas M, Panetta JC, Zhuang Y, Schuetz JD, Johnston B, Bai F, Sorrentino B, Zhou S, Houghton PJ, Stewart CF. Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo. Cancer Research. 66: 4802-7. PMID 16651435 DOI: 10.1158/0008-5472.Can-05-2915  0.701
2006 Wilson MW, Fraga CH, Fuller CE, Rodriguez-Galindo C, Mancini J, Hagedorn N, Leggas ML, Stewart CF. Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Investigative Ophthalmology & Visual Science. 47: 1269-73. PMID 16565357 DOI: 10.1167/Iovs.05-1321  0.452
2006 Anderson BD, May MJ, Jordan S, Song L, Roberts MJ, Leggas M. Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 653-9. PMID 16434546 DOI: 10.1124/Dmd.105.006536  0.326
2005 Laurie NA, Gray JK, Zhang J, Leggas M, Relling M, Egorin M, Stewart C, Dyer MA. Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 7569-78. PMID 16243833 DOI: 10.1158/1078-0432.Ccr-05-0849  0.461
2004 Stewart CF, Leggas M, Schuetz JD, Panetta JC, Cheshire PJ, Peterson J, Daw N, Jenkins JJ, Gilbertson R, Germain GS, Harwood FC, Houghton PJ. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Research. 64: 7491-9. PMID 15492275 DOI: 10.1158/0008-5472.Can-04-0096  0.583
2004 Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF, Schuetz JD. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Molecular and Cellular Biology. 24: 7612-21. PMID 15314169 DOI: 10.1128/Mcb.24.17.7612-7621.2004  0.695
2004 Leggas M, Zhuang Y, Welden J, Self Z, Waters CM, Stewart CF. Microbore HPLC method with online microdialysis for measurement of topotecan lactone and carboxylate in murine CSF. Journal of Pharmaceutical Sciences. 93: 2284-95. PMID 15295789 DOI: 10.1002/Jps.20134  0.656
2004 Assem M, Schuetz EG, Leggas M, Sun D, Yasuda K, Reid G, Zelcer N, Adachi M, Strom S, Evans RM, Moore DD, Borst P, Schuetz JD. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. The Journal of Biological Chemistry. 279: 22250-7. PMID 15004017 DOI: 10.1074/Jbc.M314111200  0.308
2002 Leggas M, Stewart CF, Woo MH, Fouladi M, Cheshire PJ, Peterson JK, Friedman HS, Billups C, Houghton PJ. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 8: 3000-7. PMID 12231547  0.459
Show low-probability matches.